Jack Shi

1.9k total citations
19 papers, 1.1k citations indexed

About

Jack Shi is a scholar working on Oncology, Biological Psychiatry and Genetics. According to data from OpenAlex, Jack Shi has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Biological Psychiatry and 4 papers in Genetics. Recurrent topics in Jack Shi's work include Tryptophan and brain disorders (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Jack Shi is often cited by papers focused on Tryptophan and brain disorders (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Jack Shi collaborates with scholars based in United States, United Kingdom and Russia. Jack Shi's co-authors include Peggy Scherle, Swamy Yeleswaram, William V. Williams, Naresh Punwani, Xuejun Chen, Yvonne Lo, Thomas Emm, Robert Newton, Lance Leopold and Janet Maleski and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and Clinical Cancer Research.

In The Last Decade

Jack Shi

18 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jack Shi United States 13 396 394 247 228 227 19 1.1k
Lichen Teng China 17 299 0.8× 109 0.3× 270 1.1× 55 0.2× 371 1.6× 63 1.0k
Hiroyuki Eda Japan 17 195 0.5× 347 0.9× 409 1.7× 42 0.2× 75 0.3× 37 994
Ji Yuan Wu United States 21 168 0.4× 666 1.7× 712 2.9× 803 3.5× 496 2.2× 44 2.1k
Hao‐Wei Teng Taiwan 21 154 0.4× 788 2.0× 576 2.3× 47 0.2× 23 0.1× 73 1.4k
Man‐Hsin Hung Taiwan 21 214 0.5× 488 1.2× 537 2.2× 59 0.3× 20 0.1× 45 1.4k
Edward Baral Sweden 18 366 0.9× 458 1.2× 106 0.4× 38 0.2× 20 0.1× 75 1.0k
Thiago Trovati Maciel France 15 146 0.4× 78 0.2× 394 1.6× 201 0.9× 57 0.3× 38 898
Paola Muzi Italy 23 103 0.3× 405 1.0× 661 2.7× 37 0.2× 68 0.3× 52 1.5k
Thomas Plitz United States 10 485 1.2× 131 0.3× 197 0.8× 18 0.1× 81 0.4× 12 969

Countries citing papers authored by Jack Shi

Since Specialization
Citations

This map shows the geographic impact of Jack Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Shi more than expected).

Fields of papers citing papers by Jack Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Shi. The network helps show where Jack Shi may publish in the future.

Co-authorship network of co-authors of Jack Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Jack Shi. A scholar is included among the top collaborators of Jack Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Shi. Jack Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Wang, Fangfang, et al.. (2025). Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers. Cardiovascular Diabetology. 24(1). 399–399.
2.
3.
Gosselin, Nathalie, et al.. (2021). Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia. The Journal of Clinical Pharmacology. 62(1). 87–98. 6 indexed citations
4.
Shi, Jack, et al.. (2021). The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders. Clinical Pharmacology in Drug Development. 10(11). 1325–1334. 3 indexed citations
5.
6.
Zhang, Qiang, Yan Zhang, Jason Boer, et al.. (2017). In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions. Drug Metabolism and Disposition. 45(6). 612–623. 12 indexed citations
7.
8.
Beatty, Gregory L., Peter J. O’Dwyer, Jason Clark, et al.. (2017). First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 23(13). 3269–3276. 240 indexed citations
9.
Shi, Jack, Kevin Bowman, Xuejun Chen, et al.. (2016). Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies. The Journal of Clinical Pharmacology. 57(6). 720–729. 13 indexed citations
10.
Shi, Jack, Xuejun Chen, Naresh Punwani, William V. Williams, & Swamy Yeleswaram. (2016). Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor. The Journal of Clinical Pharmacology. 56(11). 1344–1354. 7 indexed citations
11.
Punwani, Naresh, Timothy C. Burn, Peggy Scherle, et al.. (2015). Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. British Journal of Dermatology. 173(4). 989–997. 53 indexed citations
12.
Shi, Jack, Xuejun Chen, Fiona Lee, et al.. (2014). The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. The Journal of Clinical Pharmacology. 54(12). 1354–1361. 164 indexed citations
13.
Chen, Xuejun, Jack Shi, Thomas Emm, et al.. (2013). Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clinical Pharmacology in Drug Development. 3(1). 34–42. 27 indexed citations
14.
Beatty, Gregory L., Peter J. O’Dwyer, Jason Clark, et al.. (2013). Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 31(15_suppl). 3025–3025. 34 indexed citations
15.
Punwani, Naresh, Peggy Scherle, Jack Shi, et al.. (2012). Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. Journal of the American Academy of Dermatology. 67(4). 658–664. 148 indexed citations
16.
Shi, Jack, Xuejun Chen, Ryan McGee, et al.. (2011). The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(12). 1644–1654. 123 indexed citations
17.
Fridman, Jordan S., Peggy Scherle, Robert J. Collins, et al.. (2011). Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation. Journal of Investigative Dermatology. 131(9). 1838–1844. 88 indexed citations
18.
Shi, Jack, Xuejun Chen, Thomas Emm, et al.. (2011). The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers. The Journal of Clinical Pharmacology. 52(6). 809–818. 86 indexed citations
19.
Shi, Jack, Yan Zhang, & Swamy Yeleswaram. (2010). The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nature Reviews Drug Discovery. 10(1). 75–75. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lichen Teng Breakdown of academic impact, for papers by Hiroyuki Eda Breakdown of academic impact, for papers by Ji Yuan Wu Breakdown of academic impact, for papers by Hao‐Wei Teng Breakdown of academic impact, for papers by Man‐Hsin Hung Breakdown of academic impact, for papers by Edward Baral Breakdown of academic impact, for papers by Thiago Trovati Maciel Breakdown of academic impact, for papers by Paola Muzi Breakdown of academic impact, for papers by Thomas Plitz
Rankless by CCL
2026